CorMedix Inc is a biotechnology business based in the US. CorMedix shares (CRMD) are listed on the NASDAQ and all prices are listed in US Dollars. CorMedix employs 29 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $3.83 |
|---|---|
| 52-week range | $2.65 - $7.15 |
| 50-day moving average | $3.35 |
| 200-day moving average | $4.44 |
| Wall St. target price | $22.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.74 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.83 from 2022-07-01
| 1 week (2022-06-28) | 7.58% |
|---|---|
| 1 month (2022-06-01) | N/A |
| 3 months (2022-04-05) | -31.73% |
| 6 months (2022-01-05) | -19.03% |
| 1 year (2021-07-02) | -44.81% |
|---|---|
| 2 years (2020-07-02) | -37.72% |
| 3 years (2019-07-05) | 9.19 |
| 5 years (2017-07-03) | 783.30% |
| Revenue TTM | $110,311 |
|---|---|
| Gross profit TTM | $41,998 |
| Return on assets TTM | -24.52% |
| Return on equity TTM | -39.99% |
| Profit margin | 0% |
| Book value | $1.55 |
| Market capitalisation | $149.8 million |
TTM: trailing 12 months
We're not expecting CorMedix to pay a dividend over the next 12 months.
CorMedix's shares were split on a 1:5 basis on 25 March 2019. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CorMedix shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for CorMedix shares which in turn could have impacted CorMedix's share price.
Over the last 12 months, CorMedix's shares have ranged in value from as little as $2.65 up to $7.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CorMedix's is 2.4088. This would suggest that CorMedix's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CorMedix Inc. , a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.